Home・Stock List・Codexis Inc

Codexis Inc

Closed

SectorHealthcare

1.46 -0.68

Buy Sell

Overview

Share price change

24h

Current

Min

1.44

Max

1.48

Key metrics
By Trading Economics
Income	-18M -8.7M
Sales	-24M 15M
EPS	-0.1
Profit margin	-57.083
Employees	146
EBITDA	-23M -6.4M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+575.68% upside

Dividends
By Acuity
Next Earnings	11 Aug 2026

Market Stats
By TradingEconomics
Market Cap	-72M 156M
Previous open	2.14
Previous close	1.46

News Sentiment

By Acuity

15%

85%

25 / 340 Healthcare

Codexis Inc Chart

Past performance is not a reliable indicator of future results.

Related News

7 Aug 2026, 19:36 UTC

Codexis Inc shares are lower, reflecting broader market trends amid uncertainty over monetary policy and a weaker-than-expected jobs report.

6 Aug 2026, 19:56 UTC

Codexis Inc shares are higher during Thursday's session, continuing an upward trend. The stock remains below its 20-day moving average.

5 Aug 2026, 20:06 UTC

Codexis Inc shares are higher today, reflecting positive market sentiment amid a broader uptick in equities. No specific news was identified for the movement.

4 Aug 2026, 19:56 UTC

Codexis Inc. shares are trading roughly flat, with no specific news identified. The stock remains below its 20-day moving average and near its one-month range low.

3 Aug 2026, 19:44 UTC

News

Codexis Inc has appointed David Butler, PhD, to its Strategic Advisory Board. Shares are advancing, though still below the 20-day moving average.

31 Jul 2026, 20:02 UTC

Codexis Inc shares are trading lower today, continuing a broader decline. The stock is near the lower end of its one-month range.

30 Jul 2026, 20:09 UTC

Codexis Inc shares are higher today, continuing their rise since Wednesday's close. Broader market volatility is influenced by mixed economic signals.

29 Jul 2026, 19:47 UTC

Macro Event

Codexis Inc shares are lower amid broader market declines and heightened volatility following the Federal Reserve's decision to keep interest rates steady.

28 Jul 2026, 19:51 UTC

Codexis Inc. shares are trading lower today, reflecting a downward trend since Monday, with a notable decline from an earlier session high.

27 Jul 2026, 19:21 UTC

News

Codexis Inc shares are higher today, supported by early customer orders and interest from CDMOs. The stock remains up since Friday's close.

24 Jul 2026, 19:01 UTC

News

Codexis Inc shares are lower following a public offering of 16.67 million shares at $1.50 each, below Thursday's close of $1.99.

23 Jul 2026, 23:51 UTC

News

Codexis Inc announced a public offering of common stock, contributing to a notable decline in shares during after-market trading.

22 Jul 2026, 20:01 UTC

Codexis Inc shares are lower during Wednesday's session, continuing a trend of declines since Tuesday's close. The stock remains below its 20-day moving average.

Peer Comparison

Price change

Codexis Inc Forecast

Price Target

By TipRanks

575.68% upside

12 Months Forecast

Average 10 USD 575.68%

High 11 USD

Low 9 USD

Based on 3 Wall Street analysts offering 12 month price targets forCodexis Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

3 ratings

Buy

Hold

Sell

Based on 3 analysts giving stock ratings to Codexis Inc - Dist in the past 3 months.

Sentiment

By Acuity

25 / 340 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Codexis Inc

Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, the company is currently developing its proprietary ECO Synthesis(tm) manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.